To clarify the molecular mechanisms underlying cisplatin resistance in bladder cancer, a total of 31 metastatic bladder cancer patients were included, and HIPK2 expression level was assayed after cisplatin-based combination chemotherapy. Here, HIPK2 is linked to urinary bladder cancer.